Q2 Earnings Forecast for Nuvalent Issued By Leerink Partnrs

Nuvalent, Inc. (NASDAQ:NUVL) – Investment analysts at Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for Nuvalent in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the company will post earnings per share of ($1.17) for the quarter. The consensus estimate for Nuvalent’s current full-year earnings is ($3.86) per share. Leerink Partnrs also issued estimates for Nuvalent’s Q3 2025 earnings at ($1.18) EPS and Q4 2025 earnings at ($1.10) EPS.

Several other equities research analysts also recently commented on NUVL. HC Wainwright reiterated a “buy” rating and set a $110.00 target price on shares of Nuvalent in a report on Friday, January 17th. Wedbush reiterated an “outperform” rating and issued a $115.00 target price on shares of Nuvalent in a research report on Monday, January 13th. UBS Group started coverage on Nuvalent in a research report on Thursday, October 24th. They issued a “neutral” rating and a $100.00 target price for the company. Finally, BMO Capital Markets boosted their price objective on Nuvalent from $132.00 to $134.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. One analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Nuvalent currently has an average rating of “Moderate Buy” and a consensus price target of $112.36.

Nuvalent Stock Performance

Nuvalent stock opened at $86.70 on Friday. Nuvalent has a 12 month low of $61.79 and a 12 month high of $113.51. The stock’s 50-day moving average is $83.93 and its 200-day moving average is $87.87.

Nuvalent (NASDAQ:NUVL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.35). During the same period in the previous year, the business earned ($0.59) earnings per share.

Hedge Funds Weigh In On Nuvalent

Several institutional investors and hedge funds have recently bought and sold shares of the business. FMR LLC boosted its holdings in shares of Nuvalent by 8.9% during the third quarter. FMR LLC now owns 9,654,352 shares of the company’s stock worth $987,640,000 after purchasing an additional 786,257 shares during the period. Wellington Management Group LLP boosted its stake in shares of Nuvalent by 65.5% during the 3rd quarter. Wellington Management Group LLP now owns 1,011,837 shares of the company’s stock valued at $103,511,000 after buying an additional 400,402 shares during the period. Geode Capital Management LLC grew its holdings in shares of Nuvalent by 9.4% during the 3rd quarter. Geode Capital Management LLC now owns 855,610 shares of the company’s stock valued at $87,546,000 after acquiring an additional 73,429 shares in the last quarter. Fred Alger Management LLC increased its stake in shares of Nuvalent by 8.6% in the third quarter. Fred Alger Management LLC now owns 627,742 shares of the company’s stock worth $64,218,000 after acquiring an additional 49,612 shares during the last quarter. Finally, Candriam S.C.A. raised its holdings in shares of Nuvalent by 15.6% during the fourth quarter. Candriam S.C.A. now owns 368,095 shares of the company’s stock worth $28,814,000 after acquiring an additional 49,728 shares in the last quarter. Hedge funds and other institutional investors own 97.26% of the company’s stock.

Insider Transactions at Nuvalent

In related news, Director Matthew Shair sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $96.22, for a total value of $192,440.00. Following the completion of the sale, the director now owns 222,522 shares in the company, valued at approximately $21,411,066.84. This represents a 0.89 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO James Richard Porter sold 27,000 shares of the business’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $86.61, for a total transaction of $2,338,470.00. Following the sale, the chief executive officer now directly owns 188,113 shares in the company, valued at approximately $16,292,466.93. This trade represents a 12.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 83,800 shares of company stock valued at $6,812,164 over the last three months. Company insiders own 12.52% of the company’s stock.

About Nuvalent

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.